Boehringer Ingelheim expands its presence in Saudi Arabia

Boehringer Ingelheim has opened its new offices in Jeddah.
Expanding its presence in the Kingdom, this new office opening marks a major milestone in the long established partnership between Boehringer and Cigalah offering international quality therapies.
This milestone is described as another successful marker of Boehringer Ingelheim’s commitment to the Kingdom and the region.
Boehringer Ingelheim Country Head Saudi Arabia Mohamed Bayoumy commented: “We are delighted to be opening our new office in the Kingdom with our strategic partner Cigalah. Our plans for the Kingdom are and have always been ambitious. We are keen to provide innovative therapies to the Saudi market and we aim to play a bigger and meaningful role in servicing the patients.”
Abdel Aziz Al-Serafy, CEO, consultant of Cigalah Group, said: “This is a very exciting development for us. The health care demands are growing in the country and we are eager to use our partnership to better serve the country.”
The office was inaugurated by Al-Serafy and Mohammed Al-Tawil, Boehringer Ingelheim GM NEMEA, in the presence of Bayoumy and senior management team from both companies.
The growth of the Kingdom’s economy over the past few years, the rapidly growing urban population, and dramatic rise in conditions such as diabetes and obesity have fueled demands for more and better health care.
Bayoumy added: “Our commitment to excellence and research into patient populations makes us confident that our medications will continue to earn the confidence of health care professionals and patients alike in the years to come. We follow a focused strategy with three lines of therapies for cardiovascular, respiratory diseases and diabetes. This targeted approach gives us the capability to put our intelligence to use effectively and live up to our commitment.”
Boehringer is especially committed to research into patient populations in order to improve understanding of conditions and patient experiences.